Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [14C]-CC-90001 in Healthy Male Subjects
NCT04655898Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CC-90001 in idiopathic pulmonary fibrosis (IPF), sponsored by Celgene Corporation. Primary endpoints: Pharmacokinetics - Total [14C]-RA at 216 hours, Pharmacokinetics - Cumulative excretion of total [14C]-RA at 13 days and 6 more. Started Dec 2020; status: completed.
02
Drugs
CC-90001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04655898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655898.